Your browser doesn't support javascript.
loading
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Weitz, Jeffrey I; Szekanecz, Zoltán; Charles-Schoeman, Christina; Vranic, Ivana; Sahin, Burak; Paciga, Sara A; Wang, Zhenyu; Hyde, Craig; Martin, David A.
Afiliação
  • Weitz JI; McMaster University, Hamilton, Ontario, Canada.
  • Szekanecz Z; The Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
  • Charles-Schoeman C; Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Vranic I; Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Sahin B; Global Safety, Pfizer Ltd, Tadworth, UK.
  • Paciga SA; Immunology & Inflammation Medical Affairs, Pfizer Inc, Istanbul, Turkey burak.sahin@pfizer.com.
  • Wang Z; Biostatistics, Pfizer Inc, Groton, Connecticut, USA.
  • Hyde C; Immunology & Inflammation Research, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Martin DA; Biostatistics, Pfizer Inc, Groton, Connecticut, USA.
RMD Open ; 8(2)2022 11.
Article em En | MEDLINE | ID: mdl-36323490

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Tromboembolia Venosa Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Tromboembolia Venosa Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article